Evidence map›Paper›PMID 40726147›Full record

ArticleNeuro-oncology2025

A cycling, progenitor-like cell population at the base of atypical teratoid rhabdoid tumor subtype differentiation trajectories.

Enrique Blanco-Carmona, Irene Paassen, Jiayou He, Jeff DeMartino, Annette Büllesbach, Nadia Anderson, Juliane L Buhl, Aniello Federico, Monika Mauermann, Mariël Brok and 19 more

Abstract read
In one paragraph

Article in Neuro-oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

29 authors.

Enrique Blanco-CarmonaGerman Cancer Research Center (DKFZ) and German Cancer Consortium (DKTK), Heidelberg, Germany.ORCID 0000-0002-1208-1691
Irene PaassenOncode Institute, Utrecht, the Netherlands.ORCID 0009-0000-7737-3292
Jiayou HeOncode Institute, Utrecht, the Netherlands.ORCID 0009-0006-7198-2381
Jeff DeMartinoOncode Institute, Utrecht, the Netherlands.ORCID 0000-0001-7366-4789
Annette BüllesbachGerman Cancer Research Center (DKFZ) and German Cancer Consortium (DKTK), Heidelberg, Germany.
Nadia AndersonOncode Institute, Utrecht, the Netherlands.
Juliane L BuhlOncode Institute, Utrecht, the Netherlands.
Aniello FedericoGerman Cancer Research Center (DKFZ) and German Cancer Consortium (DKTK), Heidelberg, Germany.
Monika MauermannGerman Cancer Research Center (DKFZ) and German Cancer Consortium (DKTK), Heidelberg, Germany.
Mariël BrokOncode Institute, Utrecht, the Netherlands.
Karin StraathofGreat Ormond Street Biomedical Research Centre, London, UK.
Sam BehjatiCambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
Rajeev VibhakarChildren's Hospital Colorado, Aurora, CO, USA.
Andrew M DonsonChildren's Hospital Colorado, Aurora, CO, USA.
Nicholas K ForemanChildren's Hospital Colorado, Aurora, CO, USA.
McKenzie ShawDepartment of Pediatric Oncology, Dana-Farber Boston Children's Cancer and Blood Disorders Center, Boston, MA, USA.
Michael C FrühwaldBavarian Cancer Research Center (BZKF), Augsburg, Germany.
Andrey KorshunovClinical Cooperation Unit Neuropathology, German Cancer Research Center (DKFZ), German Consortium for Translational Cancer Research (DKTK), Heidelberg, Germany.
Martin HasselblattInstitute of Neuropathology, University Hospital Münster, Münster, Germany.ORCID 0000-0003-2707-8484
Christian ThomasInstitute of Neuropathology, University Hospital Münster, Münster, Germany.ORCID 0000-0002-6642-7774
Niels FrankePrincess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.
Mariëtte E G KranendonkPrincess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.
Eelco W HovingPrincess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.
Natalie JägerGerman Cancer Research Center (DKFZ) and German Cancer Consortium (DKTK), Heidelberg, Germany.
Pascal D JohannBavarian Cancer Research Center (BZKF), Augsburg, Germany.
Stefan M PfisterDepartment of Pediatric Hematology and Oncology, Heidelberg University Hospital and NCT, Heidelberg, Germany.
Mariella G FilbinDepartment of Pediatric Oncology, Dana-Farber Boston Children's Cancer and Blood Disorders Center, Boston, MA, USA.
Marcel KoolUniversity Medical Center Utrecht (UMCU), Utrecht, the Netherlands.ORCID 0000-0002-6557-5468
Jarno DrostUtrecht University, Division Cell Biology, Metabolism & Cancer, Department Biomolecular Health Sciences, Faculty of Veterinary Medicine, Utrecht, the Netherlands.ORCID 0000-0002-2941-6179

Funding

Deutsche Forschungsgemeinschaft JO 1598/1-1
6 · The paper itself

Abstract

backgroundAtypical teratoid rhabdoid tumors (ATRTs) are highly aggressive pediatric central nervous system tumors defined by the inactivation of the SMARCB1 gene. Despite the identification of three distinct molecular subtypes, each defined by unique clinical and molecular characteristics, no subtype-specific therapeutic strategies are currently available. This highlights an urgent need to deepen our understanding of the cellular heterogeneity and developmental origins of ATRTs.

methodsWe generated a comprehensive single-nucleus transcriptomic atlas of ATRT samples, integrated it with single-nucleus ATAC-seq and spatial transcriptomics data, and validated our findings experimentally using patient-derived ATRT tumoroid models.

resultsOur analyses revealed distinct subtype-specific differentiation trajectories, each resembling different brain progenitor lineages. We identified key transcription factors that appear to drive these developmental pathways. Furthermore, a shared cycling, intermediate precursor cell (IPC)-like cell population, interspersed throughout tumors, was consistently present within all ATRT samples. We demonstrate that these subtype-specific differentiation pathways can be pharmacologically manipulated in patient-derived ATRT tumoroids. By directing tumor cells along their respective subtype-specific trajectories, we were able to induce a shift toward more differentiated, non-proliferative states.

conclusionsCollectively, our findings show that ATRTs recapitulate fetal brain signaling programs in a subtype-specific manner. This work provides a framework for understanding ATRT heterogeneity and supports the feasibility of maturation-based therapeutic strategies tailored to the molecular subtype of the tumor.

Indexed as

Biomarkers, TumorCell DifferentiationNeoplastic Stem CellsRhabdoid TumorTeratomaAnimalsCell CycleHumansSMARCB1 ProteinTranscriptomeTumor Cells, CulturedBiomarkers, TumorSMARCB1 ProteinATRTHDAC inhibitorsmaturation therapyPKC inhibitorssingle-cell multiome sequencing

Identifiers

PMID40726147
PMCPMC12916745

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.